Oncology Department, "Iuliu Hatieganu" University of Medicine and Pharmacy, 400012 Cluj-Napoca, Romania.
The Oncology Institute "Ion Chiricuta", Republicii Street, No 34-36, 400015 Cluj-Napoca, Romania.
Int J Environ Res Public Health. 2022 Apr 4;19(7):4314. doi: 10.3390/ijerph19074314.
Background: About 10,000 women are diagnosed with breast cancer and about 2000 women are diagnosed with ovarian cancer each year in Romania. There is an insufficient number of genetic studies in the Romanian population to identify patients at high risk of inherited breast and ovarian cancer. Methods: We evaluated 250 women of Romanian ethnicity with BC and 240 women of Romanian ethnicity with ovarian cancer for the presence of damaging germline mutations in breast cancer genes 1 and 2 (BRCA1 and BRCA2, respectively) using Next-Generation Sequencing (NGS) technology. Results: Of the 250 breast cancer patients, 47 carried a disease-predisposing BRCA mutation (30 patients (63.83%) with a BRCA1 mutation and 17 patients (36.17%) with a BRCA2 mutation). Of the 240 ovarian cancer patients, 60 carried a BRCA mutation (43 patients (72%) with a BRCA1 mutation and 17 patients (28%) with a BRCA2 mutation). In the BRCA1 gene, we identified 18 variants (4 in both patient groups (ovarian and breast cancer patients), 1 mutation variant in the BC patient group, and 13 mutation variants in the ovarian cancer patient group). In the BRCA2 gene, we identified 17 variants (1 variant in both ovarian and breast cancer patients, 6 distinct variants in BC patients, and 10 distinct variants in ovarian cancer patients). The prevailing mutation variants identified were c.3607C>T (BRCA1) (18 cases) followed by c.5266dupC (BRCA1) (17 cases) and c.9371A>T (BRCA2) (12 cases). The most prevalent mutation, BRCA1 c.3607C>T, which is less common in the Romanian population, was mainly associated with triple-negative BC and ovarian serous adenocarcinoma. Conclusion: The results of our analysis may help to establish specific variants of BRCA mutations in the Romanian population and identify individuals at high risk of hereditary breast and ovarian cancer syndrome by genetic testing.
在罗马尼亚,每年约有 10000 名女性被诊断患有乳腺癌,约 2000 名女性被诊断患有卵巢癌。罗马尼亚人群中进行的遗传研究数量不足,无法识别遗传性乳腺癌和卵巢癌的高危患者。方法:我们使用下一代测序(NGS)技术,对 250 名罗马尼亚裔乳腺癌患者和 240 名罗马尼亚裔卵巢癌患者进行了乳腺癌基因 1 和 2(BRCA1 和 BRCA2)种系致病变异的检测。结果:在 250 名乳腺癌患者中,47 名患者携带疾病易感性 BRCA 突变(30 名患者(63.83%)存在 BRCA1 突变,17 名患者(36.17%)存在 BRCA2 突变)。在 240 名卵巢癌患者中,60 名患者携带 BRCA 突变(43 名患者(72%)存在 BRCA1 突变,17 名患者(28%)存在 BRCA2 突变)。在 BRCA1 基因中,我们发现了 18 个变异(在卵巢癌和乳腺癌患者组中各有 4 个,在乳腺癌患者组中有 1 个突变变异,在卵巢癌患者组中有 13 个突变变异)。在 BRCA2 基因中,我们发现了 17 个变异(在卵巢癌和乳腺癌患者组中各有 1 个,在乳腺癌患者组中有 6 个不同的变异,在卵巢癌患者组中有 10 个不同的变异)。最常见的突变变异是 c.3607C>T(BRCA1)(18 例),其次是 c.5266dupC(BRCA1)(17 例)和 c.9371A>T(BRCA2)(12 例)。在罗马尼亚人群中较少见的 BRCA1 c.3607C>T 主要与三阴性乳腺癌和卵巢浆液性腺癌相关。结论:我们的分析结果有助于确定罗马尼亚人群中 BRCA 突变的具体变体,并通过基因检测识别遗传性乳腺癌和卵巢癌综合征的高危个体。